Vanguard Global Advisers
CRBU icon

Vanguard Global Advisers’s Caribou Biosciences CRBU Stock Holding History

Vanguard Global Advisers’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.2K Hold
29,101
– – ﹤0.01% 3053
2026
Q1 		$55.3K Buy
+29,101
New +$49.9K ﹤0.01% 2973

Other funds holding CRBU

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Global Advisers's CRBU Position: Q2 2026 in Review

Vanguard Global Advisers held its Caribou Biosciences (CRBU) position steady in Q2 2026 at 29,101 shares worth $51.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3053.

Vanguard Global Advisers first reported a position in CRBU in Q1 2026 and has held it in 2 quarters since. The position peaked at $55.3K in Q1 2026. 135 funds tracked by Wall St. Rank hold CRBU as of Q2 2026.

  • Vanguard Global Advisers held 29,101 shares of Caribou Biosciences worth $51.2K as of Q2 2026.
  • Vanguard Global Advisers left its Caribou Biosciences share count unchanged in Q2 2026.
  • Caribou Biosciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3053 holding.
  • Vanguard Global Advisers first reported a position in Caribou Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Caribou Biosciences position peaked at $55.3K in Q1 2026.
  • 135 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.